CF-Carvacrol 

CF-Carvacrol is an orally active lipid-lowering agent synthesized by merging the pharmacophores of Carvacrol (HY-N0711) and Clofibric acid (HY-B1415). CF-Carvacrol has a good affinity for PPAR-α. CF-Carvacrol has significant hypolipidemic activity and may exert antioxidant and anti-inflammatory activity by activating the Nrf2/HO-1 signaling pathway to reduce liver injury. CF-Carvacrol can be used for the study of CF-induced liver damage^[1].

CF-Carvacrol (46.3-185.2 mg/kg (0.1335-0.534 mmol/kg), i.g. daily, 7 days) demonstrates a significant and dose-dependent lipid-lowering effect in hyperlipidemic Kunming (KM) mice^[1].
CF-Carvacrol (572.3 g/kg (1.65 mol/kg), i.g. daily, a month) decreases AST, ALT, and AKP levels in mouse plasma, mitigates oxidative stress and inflammation, and ameliorates liver tissue morphology in KM mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

346.85

C₂₀H₂₃ClO₃

CC(C1=CC(OC(C(C)(OC2=CC=C(C=C2)Cl)C)=O)=C(C=C1)C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shi X, et al. Optimization of clofibrate by carvacrol results in a new hypolipidemic compound with low hepatic injury. Bioorg Med Chem Lett. 2025 May 1;120:130116./  [Content Brief]